Havrix (hepatitis A vaccine, inactivated) / GSK - LARVOL DELTA

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (clinicaltrials.gov) - P4 | N=129 | Terminated | Sponsor: Oregon Health and Science University | Active, not recruiting ➔ Terminated; Low enrollment.

Trial termination • Infectious Disease • Novel Coronavirus Disease • Psoriatic Arthritis • Rheumatology • IL17A • IL23A

Immunogenicity and safety of inactivated TZ84- vs. HM175-based hepatitis A vaccines in pediatric populations: A systematic review and meta-analysis. (PubMed, Hum Vaccin Immunother) - "Evidence was limited by the small number of unique randomized cohorts, geographic concentration in China, heterogeneity across studies, and reliance on surrogate immunogenicity outcomes. Overall, available evidence suggests that TZ84-based hepatitis A vaccines (HAPIBEV™/HEALIVE®) are associated with higher reported antibody responses and greater reported antibody persistence than the HM175-based vaccine (HAVRIX®) in children and adolescents, with comparable safety profiles.Registration: PROSPERO CRD420251154480."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Inflammation • Pediatrics

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

Long-Term Persistence of Hepatitis A Virus Immunity in Healthcare Workers Upto 25 Years After Vaccination. (PubMed, J Viral Hepat) - "We conducted a prospective cohort study among healthcare personnel and medical students vaccinated with either a monovalent HAV vaccine (Havrix, Avaxim) or a combined HAV/HBV vaccine (Twinrix) between 1996 and 2003 at Bari University Hospital, Italy. These findings demonstrate that protective HAV antibody levels persist for more than two decades after vaccination. Both monovalent and bivalent vaccines confer durable immunity, supporting the continued inclusion of HAV vaccination in national immunisation programs and occupational health strategies."

Journal • Infectious Disease • Inflammation

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2360 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | Trial completion date: May 2027 ➔ Oct 2027 | Trial primary completion date: May 2027 ➔ Oct 2027

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis. (PubMed, Ital J Pediatr) - "Healive appears to be effective and safe for preventing hepatitis A, providing at least five years of protection. This review underscores the importance of ongoing research to optimize hepatitis A vaccination strategies, including standardized assays for antigen content, clarification of protective antibody levels, and large-scale trials in regions of intermediate endemicity."

Journal • Retrospective data • Infectious Disease • Inflammation • Pediatrics

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (clinicaltrials.gov) - P4 | N=129 | Active, not recruiting | Sponsor: Oregon Health and Science University | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Jan 2025 ➔ Apr 2025

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Psoriatic Arthritis • Rheumatology • IL17A • IL23A

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Trial completion date: May 2027 ➔ Aug 2027 | Trial primary completion date: May 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

EFFICACY AND DURABILITY OF HEPATITIS A VACCINATION IN PATIENTS WITH ADVANCED FIBROSIS AND CIRRHOSIS: A RANDOMIZED-CONTROLLED TRIAL (DDW 2025) - "Using Havrix TM 1440, blood samples were collected at baseline and at 1, 6, 7, and 12 months post-vaccination to measure anti-HAV antibody levels both qualitatively and quantitatively...Future analyses of quantitative anti-HAV antibody levels will provide deeper insights into the optimal vaccination strategies and long-term immunity for this high-risk population. This study does have several limitations, as it excluded patients with CTP C cirrhosis and post-liver transplantation, who typically exhibit greater immune dysfunction."

Clinical • Metastases • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

HAV-RCT: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (clinicaltrials.gov) - P3 | N=120 | Completed | Sponsor: Chiang Mai University | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Dec 2024

Head-to-Head • Trial completion • Trial completion date • Infectious Disease • Inflammation

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

The Immunological and Epidemiological Effectiveness of Pediatric Single-Dose Vaccination against Hepatitis A 9 to 11 Years after Its Implementation in the Tyva Republic, the Russian Federation. (PubMed, Vaccines (Basel)) - "The anti-HAV IgG antibodies were determined in two independent cohorts of children who were vaccinated with a single dose of monovalent pediatric inactivated vaccine (HAVRIX® 720 EU) in Tyva in 2012 and recruited 9 years (Year 9 Cohort) and 11 years (Year 11 Cohort) after immunization...However, the limited monitoring of HAV RNA in sewage and environmental samples demonstrated the ongoing circulation of both the regional epidemic strain of HAV genotype IA and another genotype IA strain imported recently from other parts of the Russian Federation, probably due to subclinical infections in non-vaccinated children under 3 years of age. Taken together, these data indicate the effectiveness of the single-dose HAV vaccination strategy but suggest the need to expand the vaccination program to include children aged 12 months and older to achieve maximum effectiveness."

Journal • Hepatology • Infectious Disease • Inflammation • Pediatrics

HAV-RCT: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (clinicaltrials.gov) - P3 | N=120 | Active, not recruiting | Sponsor: Chiang Mai University | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Head-to-Head • Hepatology • Infectious Disease • Inflammation

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Mahidol University | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation

HAV-RCT: Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Chiang Mai University

Head-to-Head • New P3 trial • Hepatology • Infectious Disease • Inflammation

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Mahidol University

New P4 trial • Fibrosis • Hepatology • Immunology • Infectious Disease • Inflammation

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) (clinicaltrials.gov) - P4 | N=129 | Active, not recruiting | Sponsor: Oregon Health and Science University | Recruiting ➔ Active, not recruiting | N=400 ➔ 129 | Trial primary completion date: Aug 2024 ➔ Jan 2025

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Psoriatic Arthritis • Rheumatology • IL17A • IL23A

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (clinicaltrials.gov) - P3 | N=2637 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Sep 2023 | Trial primary completion date: Oct 2024 ➔ Sep 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections • Pediatrics